Maze
Maze Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for diseases like chronic kidney disease using its Compass Platform.
Secondary Market Price
How Maze Measures Up
To help you manage your Maze equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Maze's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Maze Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Maze's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, cardiovascular, and related metabolic diseases. The company uses its Compass platform to identify and characterize genetic variants and link them to the biological pathways that drive disease. Its pipeline includes two lead programs: MZE829, a treatment for chronic kidney disease, and MZE782, a treatment for both chronic kidney disease and phenylketonuria (PKU). Founded in 2018, Maze Therapeutics is based in South San Francisco and has advanced its primary programs into the clinical stage.
Looking forward, Maze Therapeutics is focused on progressing its pipeline of precision medicines. The company recently presented additional pharmacokinetic data from its Phase 1 clinical trial of MZE782 at the American Society of Nephrology’s Kidney Week and its CEO presented at the J.P. Morgan Healthcare Conference. On October 11, 2025, the company raised $150 million in a post-IPO equity round. Sources also indicate a potential IPO filing in the first quarter of 2026.
- Felicis Ventures
- Emergence Capital
- Amplify Partners
- Partech
- Seedcamp
- Atlassian Ventures
- Zoom Ventures
- HubSpot Ventures
- Anne Raimondi
- Justin Bauer
- Co-Founder, Jonathan Widawski
- Co-Founder, Thomas Mary
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Maze worth joining?
Deciding to join a startup like Maze involves evaluating its potential and how its equity package fits into your financial goals. Tools like Prospect can help you analyze the value of a potential equity offer and compare it to other opportunities.
What should I do with my Maze stock?
Managing your Maze stock requires a personalized strategy that considers your financial situation, tax implications, and the company's future prospects. Platforms like Prospect offer customized option exercise and stock sale strategies to help you maximize your equity's value.
Can you sell Maze stock?
As Maze is a private company, selling stock is typically possible through company-approved tender offers or on secondary markets, though it is less straightforward than with public stocks. Prospect provides tools to help you navigate sales opportunities like tender offers and determine the most tax-optimal shares to sell.
How can I find the value of my Maze stock?
The value of private stock like Maze's is often determined by its latest 409A valuation, recent funding rounds, or secondary market transactions. Prospect uses proprietary predictive models, trained on venture capital data, to forecast the future value of your shares and help you understand their potential worth.
What is Maze's equity worth?
The precise worth of Maze's equity fluctuates based on company performance, market conditions, and investor demand. To get a data-driven estimate, you can use services like Prospect, which projects a likely range of outcomes for your equity using machine learning models.
What is Maze's stock ticker symbol?
Since Maze is a private company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Maze stock?
Selling private Maze stock is sometimes possible through tender offers or secondary markets, while buying it is typically restricted to employees or accredited investors in specific funding rounds. For employees holding equity, Prospect can help create tax-efficient strategies for when you decide to exercise options or sell shares.
What is the criteria to buy or invest in Maze stock?
Investing in a private company like Maze is generally limited to accredited investors participating in funding rounds or employees who receive equity as part of their compensation. These opportunities are not typically available to the general public until the company goes public.
